[{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Brown Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Eunice Kennedy Shriver National Institute Of Child Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Funding","leadProduct":"Brown Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health","highestDevelopmentStatusID":"1","companyTruncated":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Regenexx","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Biorestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Biorestorative Therapies"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Galen Patient Recruitment","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Galen Patient Recruitment","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Galen Patient Recruitment"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"PRC Clinical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ PRC Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ PRC Clinical"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Biorestorative Therapies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic cervical discogenic pain.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 27, 2025

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          November 13, 2024

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Company is developing a novel exosome-based biologic program for the treatment of obesity and aims to initiate first-in-human clinical studies before the end of the year.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 08, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          April 16, 2024

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The partnership aims to accelerate the completion of patient enrollment in the ongoing Phase 2 study of BioRestorative's primary clinical candidate, BRTX-100, for chronic lumbar disc disease.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          April 08, 2024

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Galen Patient Recruitment

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          September 08, 2023

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The Company intends to use the proceeds for its clinical trials with respect to its lead cell therapy candidate, BRTX-100, intended for the treatment of chronic lumbar disc disease, and for pre-clinical research and development with respect to its metabo...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          July 11, 2023

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Titan Partners Group LLC

                          Deal Size : $2.1 million

                          Deal Type : Public Offering

                          blank

                          09

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 07, 2023

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          June 27, 2023

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank